Back to Search
Start Over
Sagimet Biosciences price target lowered by $4 at Goldman Sachs, here's why
- Source :
- The Fly. May 16, 2024
- Publication Year :
- 2024
-
Abstract
- Goldman Sachs lowered the firm's price target on Sagimet Biosciences to $23 from $27 and keeps a Buy rating on the shares following the Q1 report. The company's progress continues [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.794035984